Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Return on Equity (2016 - 2021)

Historic Return on Equity for Neurocrine Biosciences (NBIX) over the last 11 years, with Q3 2021 value amounting to 0.07%.

  • Neurocrine Biosciences' Return on Equity fell 400.0% to 0.07% in Q3 2021 from the same period last year, while for Sep 2021 it was 0.07%, marking a year-over-year decrease of 400.0%. This contributed to the annual value of 0.07% for FY2019, which is 200.0% up from last year.
  • Latest data reveals that Neurocrine Biosciences reported Return on Equity of 0.07% as of Q3 2021, which was down 400.0% from 0.01% recorded in Q2 2021.
  • Over the past 5 years, Neurocrine Biosciences' Return on Equity peaked at 0.27% during Q2 2020, and registered a low of 0.74% during Q2 2017.
  • Moreover, its 5-year median value for Return on Equity was 0.04% (2019), whereas its average is 0.1%.
  • Its Return on Equity has fluctuated over the past 5 years, first tumbled by -4500bps in 2017, then soared by 6000bps in 2018.
  • Over the past 5 years, Neurocrine Biosciences' Return on Equity (Quarter) stood at 0.4% in 2017, then skyrocketed by 112bps to 0.05% in 2018, then increased by 30bps to 0.06% in 2019, then grew by 1bps to 0.06% in 2020, then rose by 20bps to 0.07% in 2021.
  • Its last three reported values are 0.07% in Q3 2021, 0.01% for Q2 2021, and 0.05% during Q1 2021.